SGMT — Sagimet Biosciences Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1400118 ·
Last close
$6.48
Market Cap
$396.47M
52W High
$9.37
52W Low
$4.50
ADV30
839,530
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,713,000 | -10,650,000 | 107,755,000 | 36,626,000 | 5,297,000 |
| Dec 2025 | 0 | — | -10,765,000 | -9,568,000 | 116,482,000 | 35,021,000 | 5,101,000 |
| Sep 2025 | 0 | — | -14,334,000 | -12,908,000 | 128,401,000 | 32,496,000 | 9,146,000 |
| Jun 2025 | 0 | — | -11,925,000 | -10,386,000 | 137,407,000 | 42,327,000 | 7,247,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,725,000
Investing CF
$11,359,000
Financing CF
$275,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-356,999,000
Inventory
—
Receivables
—
ST Investments
$67,913,000
EBIT TTM
$-48,737,000
Pretax Income TTM
$-43,512,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,889,000 | -51,038,000 | 116,482,000 | 5,101,000 | — | -45,650,000 |
| Dec 2024 | 0 | -54,454,000 | -45,567,000 | 160,259,000 | 4,454,000 | — | -42,435,000 |
| Dec 2023 | 2,000,000 | -30,740,000 | -27,876,000 | 96,719,000 | 5,654,000 | — | -23,766,000 |
| Dec 2022 | 0 | -31,055,000 | -30,499,000 | 33,031,000 | 219,981,000 | — | -24,490,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.31
Max Pain — expiry 2026-07-17
max pain strike: $5.00 · spot: $6.47 · call oi: 3,360 · put oi: 760
Expected Move to 2026-07-17:
±$1.55
(23.96%) —
implied range
$4.92 –
$8.02
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYDY | CytoDyn Inc. | $397.22M | $0.29 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $394.57M | $6.04 | — |
| MNPR | Monopar Therapeutics | $400.40M | $59.77 | — |
| CTNM | Contineum Therapeutics, Inc. | $388.76M | $11.88 | — |
| INDP | Indaptus Therapeutics, Inc. | $405.41M | $3.58 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
2026-06-04 13:55 · Yahoo
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
2026-05-27 11:00 · Yahoo
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
2026-05-21 13:55 · Yahoo
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-13 11:00 · Yahoo
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-12 11:30 · Yahoo
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
2026-05-11 11:00 · Yahoo
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
2026-05-05 16:00 · Yahoo
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
2026-05-05 13:55 · Yahoo
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise
2026-05-01 04:07 · Yahoo
Why Sagimet Biosciences Stock Is Soaring Today
2026-04-27 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.